bioRxiv Science⌕ Search

Biology subjects

Black, C. C.

Publications and source records attributed to Black, C. C..

2 recordsLinked to original sources

X-SPATIO: An Explanatory Deep Learning Pipeline for the Prediction and Visualization of Spatially Resolved Biomarker Expression in Triple-Negative Breast Cancer

Histopathologic evaluation remains central to cancer diagnosis and treatment planning, yet the molecular programs underlying distinct tissue morphologies are not routinely accessible in clinical workflows. Spatial transcriptomic/proteomic platforms provide region-specific molecular measurements but are limited by cost, throughput, and scalability. Most computational pathology models rely on either bulk tissue-based gene expression or a focused gene/protein expression-panel prediction, thereby obscuring subregion-specific morpho-molecular relationships and limiting spatial interpretation of a wider gene/protein expression network. This limitation is particularly significant in triple-negative breast cancer (TNBC), which exhibits pronounced spatial heterogeneity across tumor, stroma, and immune compartments. We developed X-SPATIO, a spatially compatible computational pipeline designed to directly link hematoxylin and eosin (H&E) morphology with region-matched mRNA and protein expression. The model was trained on H&E-defined regions of interest paired with spatially-resolved transcriptomic and proteomic data obtained from GeoMx Digital Spatial Profiler. Using a multiple-instance learning approach, X-SPATIO captures morpho-molecular associations, generating spatio-morphologic attention maps that indicate predictive tissue regions. X-SPATIO demonstrated strong performance across biologically relevant spatial biomarkers, achieving area under the curve values ranging [0.79, 0.97]. Attention maps revealed spatial patterns consistent with known biology, indicating alignment between learned features and tissue organization. By integrating spatial molecular ground truth with routine histopathology, X-SPATIO enables cost-effective inference of spatial biomarker expression and establishes a foundation for biologically grounded discovery and precision oncology in TNBC.

pathology↗

Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques

Previously, ivermectin (1-10 mg/kg) was shown to inhibit liver-stage development of Plasmodium berghei in orally dosed mice. Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (IC50 = 10.42 M) and hypnozoites (IC50 = 29.24 M) in primary macaque hepatocytes when administered in high-dose prophylactically but not when administered in radical cure mode. The safety, pharmacokinetics, and efficacy of oral ivermectin (0.3, 0.6, and 1.2 mg/kg) with and without chloroquine (10 mg/kg) administered for seven consecutive days was evaluated for prophylaxis or radical cure of Plasmodium cynomolgi liver-stages in Rhesus macaques. No inhibition or delay to blood-stage P. cynomolgi parasitemia was observed at any ivermectin dose (0.3, 0.6, and 1.2 mg/kg). Ivermectin (0.6 and 1.2 mg/kg) and chloroquine (10 mg/kg) in combination were well-tolerated with no adverse events and no significant pharmacokinetic drug-drug interactions observed. Repeated daily ivermectin administration for seven days did not inhibit ivermectin bioavailability. It was recently demonstrated that both ivermectin and chloroquine inhibit replication of the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in vitro. Further ivermectin and chloroquine trials in humans are warranted to evaluate their role in Plasmodium vivax control and as adjunctive therapies against COVID-19 infections.

pharmacology and toxicology↗